mAbxience
Switzerland - LuganoBiotechnology
Focus: mAbxience is a Swiss-based biosimilar and monoclonal antibody developer focused on oncology and immunology with 51-200 employees. The company operates as a private biotech firm with a pipeline-driven model centered on biosimilar mAbs and novel therapeutics.
Profile data last refreshed Yesterday · AI intelligence enriched 2w ago
Funding Stage
PRIVATE
Employees
51-200
Open Jobs
0
About mAbxience
AI assessmentNot HiringNo open roles listed right now. Follow mAbxience to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthStrong
Pipeline
Late-stage
6 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
PHASE_1
Clinical Trials (1)
NCT04238650A Pharmacokinetic Study Comparing MB02 And EU Avastin® In Healthy Male Volunteers
Phase 1Help build intelligence for mAbxience
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.